Repligen Corporation develops and markets bioprocessing systems and technologies for use in the biologic drug manufacturing process in North America, Europe, Asia Pacific, and internationally. The company is headquartered in Waltham, Massachusetts.
| Revenue (TTM) | $763.34M |
| Gross Profit (TTM) | $405.63M |
| EBITDA | $134.24M |
| Operating Margin | 8.90% |
| Return on Equity | 2.51% |
| Return on Assets | 1.18% |
| Revenue/Share (TTM) | $13.56 |
| Book Value | $37.33 |
| Price-to-Book | 3.51 |
| Price-to-Sales (TTM) | 9.32 |
| EV/Revenue | 9.55 |
| EV/EBITDA | 41.32 |
| Quarterly Earnings Growth (YoY) | 47.90% |
| Quarterly Revenue Growth (YoY) | 14.80% |
| Shares Outstanding | $48.92M |
| Float | $53.37M |
| % Insiders | 5.25% |
| % Institutions | 120.01% |
Volatility is currently expanding
RGEN tops Q2 earnings and revenue estimates, lifts its 2026 revenue and EPS outlook, and sees shares jump after stronger-than-expected results.
Repligen NASDAQ: RGEN reported second-quarter 2026 revenue of $204 million, up 12% year over year on a reported basis and 13% organically, as demand for proteins, analytics products and recurring consumables supported growth. The company also raised its full-year organic revenue growth and adjusted earnings outlook, citing continued order momentum and improved visibility into the second half.
Repligen (RGEN) came out with quarterly earnings of $0.54 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.37 per share a year ago.
WALTHAM, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter of 2026, covering the three-month period ended June 30, 2026. The Company is also providing updated financial guidance for the full year 2026.
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of BioLife Solutions, Inc. (NasdaqCM: BLFS) to Repligen Corporation (NasdaqGS: RGEN). Under the terms of the proposed transaction, shareholders of BioLife will receive $11.25 in cash and 0.1442 shares of Repligen common stock for each share of BioLife that they own. KSF is seeking to determine whe.
RGEN's $1.5 billion BioLife acquisition aims to expand its cell therapy capabilities, adding biopreservation products and expected revenue and EPS benefits.
Repligen Corporation (RGEN) M&A Call Transcript
Repligen NASDAQ: RGEN said it has signed a definitive agreement to acquire BioLife Solutions in a transaction valued at approximately $1.5 billion, adding a cell therapy-focused platform that management said will expand Repligen's exposure to one of the faster-growing areas of bioprocessing.
Life sciences company Repligen Corporation (NASDAQ:RGEN) on Wednesday agreed to acquire cell processing developer BioLife Solutions Inc. (NASDAQ:BLFS) for an enterprise value of approximately $1.5 billion.
Repligen Corp said on Wednesday it would buy BioLife Solutions in a cash-and-stock deal valued at about $1.5 billion, to expand the drugmaking equipment provider's presence in the fast-growing cell therapy market.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on RGEN and any ticker you trade — then tracks every position and per-strategy win rate.
